In their interesting article, Ashraf et al 1 presented a modifying of the current treatment protocols for central retinal vein occlusion (CRVO). We want to address some issues directly related to the intravitreal therapy with anti-vascular endothelial growth factor (VEGF) agents in patients with CRVOs. The article has several shortcomings that prevent the validation of their results and that can be specifically summarized as follows:
1. Nothing was stated regarding the long-term outcomes of the intravitreal therapy with bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA, USA 4 reported that visual outcomes were no better after 24 weeks of injections of 2.0 mg ranibizumab every 4 weeks compared with injections every 4 weeks of 0.5 mg ranibizumab. However, 90% of the patients in the 2.0 mg ranibizumab group had central subfield thickness of 320 μm or less compared with 52.6% of the patients in the 0.5 mg group (P = 0.03). Considering that the presence of macular edema is mainly guided by anatomical measure data with visual changes as a secondary guide, we believe that the significant difference between the two percentages of patients emphasizes the significantly greater effectiveness of the 2.0 mg dose of ranibizumab in comparison with the 0.5 mg dose in patients with CRVO-related macular edema. 3. There were no data on the treat-and-extend (TAE) regimens with intravitreal anti-VEGF agents used in RVOs to reduce burden of treatment on patients and physicians while maintaining effectiveness in the treatment. 4. The article by Ogura et al, 5 which reported the 18-month results of the Galileo study, was not included in the reference list, although the content of this article was erroneously encompassed in the paper by Korobelnik et al, 6 which reported the 1-year results of the Galileo study. In conclusion, central/hemicentral RVO has to be considered an ophthalmic emergency. Therefore, therapy with anti-VEGF agents has to be promptly applied as soon as possible after RVO onset. Regardless of the anti-VEGF agents used (ranibizumab/aflibercept/bevacizumab), and regardless of the treatment approaches chosen (TAE/pro re nata algorithm), the efficacy of therapy depends primarily on the precociousness of the therapy after RVO diagnosis.
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We would like to thank Călugăru and Călugăru 1 for their comments on our paper, Central retinal vein occlusion: modifying current treatment protocols.
Although bevacizumab is widely used in common practice, there are no large-scale randomized control trials that have studied bevacizumab. Even the quoted paper 1 had a relatively small cohort of 57 patients. It is difficult to extrapolate recommendations especially with regard to long-term outcomes until larger studies have been conducted.
Although the 2 mg ranibizumab dose in the Relate study 2 did show a better anatomical response compared with the other doses, this was not mirrored in visual outcomes. In addition, with the absence of a commercially available 2.0 mg dose and in the context of a visual acuity guided strategy, it would be difficult to advocate quadrupling the dose of ranibizumab.
There have been no large studies that have looked into treat and extend for treating CRVO. However, we did not advocate this particular strategy. We proposed gradually extending the follow-up periods based on the data from HORIZON, which showed that in the second year patients followed up every 3 months post vision. 3 Hence with regard to certain patients following them closely would allow identification of early recurrences. Furthermore, we believe that the mandatory treatments during extension cycles typically reserved for age-related macular degeneration (AMD) is unnecessary in CRVO. In AMD, each recurrence is associated with a drop in final visual acuity as evidenced by a difference in final visual outcomes between monthly and PRN dosing regimens. 4 In diabetic macular edema and in CRVO, the pathology is quite different and as evidenced by the SHORE study, there is no difference between the patients treated using a PRN regimen and maximum monthly dose regimen. 5 Hence with regard to the treatment, PRN would seem to be the 'better' dosing option, and the standard Treat and extend would overtreat a significant number of patients.
The data from Călugăru and Călugăru 1 regarding the use of bevacizumab in cases of ischemic CRVO included 21 patients with ischemic CRVO/HRVO. These data are important, however, was not included because of the relatively small number. It would be interesting to study the effects of bevacizumab in ischemic CRVO on a larger scale.
Switching to aflibercept, 6 although still a relatively novel approach to treating resistant CRVO, has been gaining significant traction in real-world practice. It is a more appealing option than using steroids and there are mounting data that it might be a good option. 7, 8 However, this has yet to be confirmed with larger studies conducted in a prospective manner.
Finally, we appreciate the in-depth analysis and the debate with regard to treating CRVO, and we acknowledge that this is a serious disease that requires aggressive and timely intervention to preserve vision.
